NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
April 21, 2026 — Soligenix CEO advocates patient-centric drug reformulation to improve treatment access and adherence for rare diseases. Learn how subcutaneous delivery transforms chronic care.
April 21, 2026 — Soligenix CEO Dr. Christopher Schaber discusses capital discipline strategies for biotech companies in constrained funding environments, emphasizing rare disease development and value-defining milestones.
April 21, 2026 — Conley Family Dentistry in Bowie, MD launches all-ages dental care model serving toddlers to seniors. Family dentist Bowie MD residents trust offers preventive, restorative & cosmetic services.
April 21, 2026 — Carolina Braces in Raleigh expands orthodontic services with braces, Invisalign, and early treatments for all ages. Learn about personalized care and financing options.
April 21, 2026 — Oncotelic Therapeutics exemplifies biotech valuation shift, with drug pipelines recognized as financial assets under U.S. GAAP. Its 45% stake in GMP Bio, valued over $1B, highlights clinical progress enhancing balance sheets.
April 21, 2026 — NanoViricides announces its antiviral drug NV-387 may combat the global measles outbreak, citing safety in Phase I trials and efficacy in animal models as a complement to vaccines.
April 21, 2026 — Discover how molecular analysis is transforming CNS cancer diagnosis, with insights from CNS Pharmaceuticals and BioMedWire's role in disseminating breakthrough medical news to global audiences.
April 21, 2026 — Eolas Medical's AI system achieves 100% antibiotic prescribing accuracy in Nature-published study, offering solution to antibiotic resistance crisis affecting millions.
April 21, 2026 — ioTech International launches ioRinse Ultra, an oral rinse proven effective against gingivitis-causing bacteria in human saliva, challenging traditional mouthwash efficacy.
April 21, 2026 — Carolina Braces educates Raleigh patients on benefits of local orthodontists for Invisalign and braces, emphasizing proximity for better treatment outcomes and convenience.
April 21, 2026 — BioXgen announces a Regulation Crowdfunding investment offering and live webinar for its cardiac patch to prevent post-operative atrial fibrillation after open-heart surgery.
April 20, 2026 — LIXTE Biotechnology's LB-100 cancer drug enhances chemotherapy effectiveness through PP2A inhibition. Clinical trials show promise for ovarian, colon cancers & sarcoma treatment improvements.
April 20, 2026 — Cardio Diagnostics uses AI, genetics & epigenetics to transform cardiovascular disease prevention & detection. NASDAQ: CDIO company creates personalized heart health insights.
April 20, 2026 — Soligenix receives European Commission orphan drug designation for SGX945 targeting Behçet's disease, marking a key regulatory milestone for rare disease treatment development.
April 20, 2026 — Soligenix CEO advocates for patient-centric drug development, highlighting reformulation of SGX945 from IV to subcutaneous to improve access and adherence in rare disease treatment.
April 20, 2026 — Oragenics advances Phase IIa trial for ONP-002, a first-in-class intranasal treatment for concussion. Two patients enrolled in Australia trial addressing unmet need for FDA-approved mTBI therapies.
April 20, 2026 — Aditxt subsidiary Ignite Proteomics featured in Nature study showing advanced protein analytics predict breast cancer treatment outcomes better than traditional methods.
April 20, 2026 — Lantern Pharma schedules FDA meeting for LP-300 lung cancer trial amendments. AI-driven precision oncology company seeks to refine Phase 2 HARMONIC trial for EGFR patients.
April 20, 2026 — Helus Pharma announces CEO transition with Eric So as interim leader, focusing on clinical trials for mental health treatments like HLP003. Learn about the company's NSAs and impact.
April 20, 2026 — Ocumetics reports six-month results from its first-in-human study of an accommodating intraocular lens, showing vision improvements and life-changing outcomes for patients.